Compare · ARGX vs TWST
ARGX vs TWST
Side-by-side comparison of argenx SE (ARGX) and Twist Bioscience Corporation (TWST): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and TWST operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $48.52B, about 13.5x TWST ($3.58B).
- Over the past year, ARGX is up 22.3% and TWST is up 54.9% - TWST leads by 32.6 points.
- TWST has been more active in the news (8 items in the past 4 weeks vs 3 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 12 for TWST).
- Company
- argenx SE
- Twist Bioscience Corporation
- Price
- $781.78+0.74%
- $58.38+2.91%
- Market cap
- $48.52B
- $3.58B
- 1M return
- +7.01%
- +22.78%
- 1Y return
- +22.29%
- +54.85%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- 2018
- News (4w)
- 3
- 8
- Recent ratings
- 25
- 12
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Twist Bioscience Corporation
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with ImmunoPrecise Antibodies Ltd.; Victorian Clinical Genetic Services; Vivlion GmbH; and Kyowa Kirin Pharmaceutical Research, Inc. Twist Bioscience Corporation was founded in 2013 and is headquartered in South San Francisco, California.
Latest ARGX
- argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Latest TWST
- Director Starovasnik Melissa A. sold $30,915 worth of shares (500 units at $61.83) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 25,222 units (SEC Form 4)
- President and COO Finn Patrick John sold $141,026 worth of shares (2,321 units at $60.76), decreasing direct ownership by 0.82% to 281,808 units (SEC Form 4) to cover withholding tax
- Chief Executive Officer Leproust Emily M. exercised 9,671 shares at a strike of $8.82 and sold $630,957 worth of shares (9,671 units at $65.24) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 4 filed by Laponis Adam
- Twist Bioscience to Report Fiscal 2026 Second Quarter Financial Results on Monday, May 4, 2026
- SEC Form 4 filed by Laponis Adam
- SEC Form 4 filed by Laponis Adam
- SEC Form 144 filed by Twist Bioscience Corporation
- SEC Form 4 filed by Starovasnik Melissa A.
- Amendment: SEC Form SCHEDULE 13G/A filed by Twist Bioscience Corporation